What You Should Know:
- Walgreens and Freenome form a multi-year relationship to advance clinical studies of Freenome’s blood-based tests for the early detection of cancer.
- Walgreens will combine its national footprint, patient insights, compliant recruitment technology and local infrastructure to engage diverse patient populations in Freenome’s multi-cancer research program. Walgreens will initially recruit patients across diverse populations for Freenome’s Sanderson Study, which aims to evaluate blood-based early detection tests for multiple cancers.
Sanderson Study Recruiting
Walgreens will initially recruit patients across diverse populations for Freenome’s Sanderson Study, which aims to evaluate blood-based early detection tests for multiple cancers. Using Curebase’s platform, Walgreens will deliver targeted outreach to potentially eligible patients and caregivers of all backgrounds via text, email or in-person consultation at the pharmacy. After completing a pre-screen, eligible patients are invited to enroll in the study. Walgreens healthcare providers will then perform a single blood draw at one of the company’s clinical trial locations and conduct a telehealth patient follow-up one year after their participation. The Sanderson Study will enroll approximately 8,000 participants through its clinical study partner network, which includes Walgreens.
